Dioseve
Japan - TokyoBiotechnology
Focus: Dioseve is a pre-revenue Japanese biotech founded in 2024 specializing in assisted reproductive technology using oocytes derived from iPS cells. The company operates at the intersection of regenerative medicine and fertility, representing an emerging and highly specialized market segment.
Profile data last refreshed 20h ago · AI intelligence enriched 2w ago
Open Jobs
0
About Dioseve
AI assessmentNot HiringNo open roles listed right now. Follow Dioseve to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Conventional rescue in vitro maturation
Oocyte MaturationClinical Trials (1)
NCT07559357OSC Co-culture for Rescue IVM of Human GV Oocytes
N/AHelp build intelligence for Dioseve
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.